SCHEMBL5124183

SCHEMBL5124183

CNC(=O)c1cc(Oc2cccc(CCNC(=O)c3ccc(-c4ccc(Cl)c(Cl)c4)cc3)c2)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.54
RAF1 P04049 3/20 0.54
PSEN1 P49768 1/20 0.49
PSEN2 P49810 1/20 0.49
APH1B Q8WW43 1/20 0.49
NCSTN Q92542 1/20 0.49
APH1A Q96BI3 1/20 0.49
PSENEN Q9NZ42 1/20 0.49
RET P07949 1/20 0.47
ROCK2 O75116 3/20 0.45
CYP3A4 P08684 3/20 0.45
CYP2D6 P10635 3/20 0.45
CYP2C9 P11712 3/20 0.45
ROCK1 Q13464 3/20 0.45
PRKACA P17612 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
PRKX P51817 1/20 0.44
PRKCQ Q04759 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3992181 0.89 BRAF (0.54) BRAFRAF1PSEN1PSEN2APH1B
SCHEMBL3991957 0.87 BRAF (0.51) BRAFRAF1RETKDRCA1
SCHEMBL14266582 0.86 RAB9A (0.51) BRAFRAF1KDRCA1CA2
SCHEMBL5124752 0.86 KDR (0.51) BRAFRAF1KDRCA1CA2
SCHEMBL14266535 0.85 BRAF (0.54) BRAFRAF1RETTRPV1KDR
SCHEMBL3991948 0.85 KDM5B (0.51) BRAFRAF1ROCK2CYP3A4CYP2D6
SCHEMBL4289196 0.85 RAB9A (0.55) BRAFRAF1ROCK2CYP3A4CYP2D6
SCHEMBL14266605 0.85 BRAF (0.55) BRAFRAF1RETGSK3BTRPV1
SCHEMBL14273363 0.85 BRAF (0.48) BRAFRAF1RETROCK2CYP3A4
SCHEMBL3989166 0.84 RAF1 (0.70) BRAFRAF1RETGSK3BKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 US disclosed
WO-2008030448-A1 PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064729-A1 Phenethylamide derivatives with kinase inhibitory activity MAP4K5, MAP3K5, MAP4K2 BRAF 242/4885RAF1 251/4885PSEN1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.